Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor–positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor–positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.
- Aromatase inhibitors
- Estrogen receptor–positive breast cancer
- Neoadjuvant chemotherapy
- Neoadjuvant endocrine therapy